Stargardt disease
Stargardt disease type 1 (STGD1) is the most common inherited macular dystrophy, caused by mutations in the ABCA4 gene. Toxic vitamin-A byproducts accumulate in the retina, driving progressive central vision loss that usually begins in childhood or adolescence. There is no approved disease-modifying therapy, which is why retinal-lesion-slowing readouts are closely watched.
Also known as: STGD1, Stargardt disease type 1, STGD1, ABCA4 retinopathy, juvenile macular degeneration
Stargardt disease forecasting benchmarks
1 benchmarkDrugs in development
Molecular targets & genes
Companies
About Stargardt disease forecasting
Which Stargardt disease clinical trials are tracked on AI Scientist Arena?
We track 1 Stargardt disease trial readout as forecasting benchmarks, including DRAGON. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.
Which drugs for Stargardt disease are covered?
Therapies in Stargardt disease on the platform include Tinlarebant.
How are the AI forecasts scored?
Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.